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Background: Exercise-induced Pulmonary Artery Hypertension (EiPAH) represents an early phase of Pulmonary Arterial Hypertension (PAH) in which 
screening and early detection might facilitate treatment aimed at preventing progression of EiPAH to resting PAH. In this study we sought to compare 
change in 6MWD after initiation of PA targeted therapy in EiPAH and PAH patients
methods: 6 minute walk distance in meters (6MWD) was measured at baseline in consecutive patients with PAH and EiPAH ( PAH defined as mPAP 
>25 and PCWP<15 at rest, and EiPAH defined as mPAP >30 and PCWP<15 on exercise with trans pulmonary gradient >15mm of Hg ). Patients were 
then started on PA targeted therapy(Phosphodiesterase-5 Inhibitors or Endothelial Receptor Antagonists or Both) and 6MWD was measured at 6 
months.
Results: PAH patients (N=22) had baseline mPAP= 46±10,6mwd=248.45±105, after 6months of PA targeted therapy the 6mwd was significantly 
higher(287.59±108.5, p=0.003,difference 39±54;Fig1) . Similarly in EiPAH patients (N=26) had exercise mPAP = 37.25, 6mwd of 341±86, after 
6months of PA targeted therapy the 6mwd was significantly higher (371±82, p=0.001,difference 30±42; Figure 1). However the absolute change in 
6mwd between PAH and EiPAH was not statistically significant (4.25±60.5, p=0.7; Fig2)
conclusions: Clinical improvement is similar between PAH and EiPAH patients on PA targeted therapy. Starting PA targeted therapy early in EiPAH 
may be equally beneficial and might prevent progression of EiPAH to resting PAH.
 
